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Ltd. This is an open access article undAbstract Sentinel lymph node biopsy has become a well-established and commonplace prac-
tice in many oncologic disease sites as a means to stage the regional lymphatics, avoid unnec-
essary surgery and decrease patient morbidity. In the head and neck, its role is well
established for cutaneous melanoma with proven fidelity and survival benefit. Its role in use
for other sites such as oral cavity carcinoma continues to develop with promising results from
several recent trials. Although not widely adopted, the potential benefits of sentinel lymph
node biopsy in the management of oral cavity carcinoma are apparent. Refinements in tech-
nology and protocols including development of novel radiopharmaceutical tracers, routine
incorporation of detailed anatomic imaging, increasing surgeon experience and development
of new intraoperative identification aids will likely lead to improvements in the use and accu-
racy of this technique.
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Since its clinical inception in 1992, the role of sentinel
lymph node (SLN) biopsy has continued to expand across
several surgical oncologic disciplines. Currently, use of SLN
biopsy has become routine and regarded as standard of
care in clinically node-negative (cN0) cutaneous melanoma
as well as breast malignancy. The use of SLN biopsy has also
been extensively explored in the head and neck for both
cutaneous as well as mucosal malignancy, particularly oral
cavity squamous cell carcinoma (SCC), as the presence of
nodal metastasis remains the most important factor for
recurrence and survival for both melanoma and SCC.1e4
Traditional efforts to identify the presence of regional
nodal disease utilizing history, physical exam, and radio-
logic imaging lack sufficient sensitivity and specificity in
that regard. As such, the use of regional elective neck
dissection (END) has been used routinely in the surgical
management of head and neck malignancy in cases where
risk of occult metastases is significant (>20%). Unfortu-
nately such procedures are invasive, associated with sub-
stantial potential morbidity, and furthermore can be
argued as unnecessary in a large proportion of patient-
sdi.e. 70%e80% of individuals with T1 or T2 oral cavity
carcinoma who ultimately prove negative for nodal me-
tastases.5 As such, less invasive methods such as SLN bi-
opsy, which accurately predicts the status of regional
lymph node basins in cN0 patients, remains of high interest
and an active area of investigation.6,7
A SLN is defined as the first lymph node (or nodes) on a
direct lymphatic drainage pathway from a primary tumor
site, and as such, is hypothesized as the most likely location
to harbor occult metastasis.8 When identified and histo-
pathologically assessed, the SLN allows prediction of the
regional metastatic potential of that given tumor. Donald
Morton originally introduced the application of SLN biopsy
in low grade trunk and extremity melanoma as a means to
spare roughly 80% of cN0 patients unnecessary lymphade-
nectomy without sacrificing survival advantage.9e11
The adoption of SLN biopsy for head and neck cancer
sites was associated with early controversy however.
Concern for unpredictable watershed lymphatics, multiple
regional nodal basins with adjacent proximity to primary
tumors, as well nearby vital structures raised concern
regarding both feasibility and accuracy of SLN procedures in
this region and led to early hesitation in accepting its use.12
Over the past several years, however, increasing evidence
has become available supporting its use in head and neck
cancer, particularly for cutaneous melanoma as well as
mucosal SCC of the oral cavity. In 2012, the largest single
institution series of prospective data on SLN biopsy in
melanoma was published demonstrating its safety and ac-
curacy in 353 patients with a negative predictive value
(NPV) of 95.8% and no major surgical complications.13
Similarly, several prospective multi-institutional studies
have yielded promising results examining the role of SLN
biopsy in early stage oral cavity SCC.14e16 Despite seemingly
encouraging data however, routine use of SLN biopsy for
cN0 oral cavity SCC has not been widely embraced as there
remain several issues and caveats regarding its use in this
area. These are outlined in the subsequent discussion aswell as novel strategies and technologies employed or being
investigated in an effort to address several of these issues
as well as those which may serve to improve the overall




Since its inception, much attention and research has been
directed at optimizing efficacy and accuracy of SLN biopsy
procedures. Protocols for this require significant coordina-
tion and attention to detail among multiple departments
and hospital services involved in preoperative, intra-
operative, and postoperative clinical care.
Preoperative imaging
Use of perioperative imaging is commonly employed to
allow SLN identification and localization prior to surgery
and to assist with operative planning. This typically involves
preoperative peritumoral injection of a radiotracer several
hours prior to surgery. This tracer can then be visualized via
various radio-imaging lymphoscintigraphy technologies
including planar gamma camera imaging and single photon
emission computed tomography (SPECT) with or without
concomitant cross-sectional X-ray computed tomography
(CT). This tracer can also be detected during surgery using
intraoperative radio-guidance equipment such as a hand-
held gamma probe.
More specifically, conventional lymphoscintigraphy with
planar gamma camera imaging (i.e., 2D assessment), typi-
cally shows Technetium-99m-labeled (99mTc) nanocolloids
as they migrate from the injection site, identifying
lymphatic pathways and eventually SLNs. Very little
anatomic data is provided by this modality however and
only number, location, and laterality of nodal basins at risk
for metastatic disease can be inferred.8 In recent years
however, newer modalities including SPECT/CT which yield
tomographic 3D-imaging, provide surgeons with more far
more detailed and surgically relevant anatomy with regard
to SLN location. At present, SPECT is typically performed
using a single-head or dual-headed gamma camera system
which acquires a series of 2D images while incrementally
rotating 360 around the head and neck region. These im-
ages are then reconstructed into a tomographic 3D dataset
which can be subsequently viewed in any 2D orientation
(e.g., axial, sagittal or coronal SPECT). If X-ray CT images of
the head and neck are also obtained, these images can then
be used for fusion with the emission SPECT images for
anatomical localization of radiotracer deposition (i.e.,
hybrid SPECT/CT). This allows for more anatomically pre-
cise localization of radiolabeled SNL(s) with respect to the
complex anatomy of the head and neck.
Previous studies have demonstrated the clinical utility
and advantages of SPECT/CT imaging compared to con-
ventional methods.17,18 Several reports have demonstrated
that use of SPECT/CT resulted in alternations of the plan-
ned surgical approach more often than not when compared
with use of conventional 2-D lymphoscintigraphy alone.19,20
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compared to lymphoscintigraphy alone and found to be
significantly superior in melanoma by identifying more total
SLNs (2.40 vs 1.87; 95% CI 1.93e2.18), more positive SLNs
(0.34 vs 0.21; 95% CI 0.21e0.31) and resulting in an
increased 4-year disease free survival (93.9% vs 79.2%;
P Z 0.02).21 In the current era of precision medicine, it is
likely that the use of more detailed perioperative anatomic
imaging such as SPECT/CT will become more routinely
incorporated in SLN biopsy procedures.Intraoperative lymphatic mapping
Although timing can be variable, operative identification
and excision of SLNs typically occurs within a few hours of
radiotracer injection and imaging. A second method of
lymphatic mapping may be employed in the operating room
as a visual adjunct utilizing methylene blue, or similar dye
material, which is injected peritumorally prior to tumor and
SLN excision. The dye is absorbed into the lymphatics
traversing afferent lymphatic vessel(s) and eventually
depositing in the SLNs which can subsequently be identified
during dissection via both radio-guidance using hand-held
gamma probe as well as direct visualization via staining.
Prior to incision, the surgeon typically scans the regional
basin(s) using a hand-held gammaprobe to verify and confirm
localization of suspected SLNs. Often the primary tumor is
then resected first, particularly if proximity of the primary
tumor to potential adjacent SLNs might interfere with radio-
guided identification and dissection (i.e. “shine-through ef-
fect” referring to primary tumor radio-activity obscuring
nearby radio-active SLNs therefore limiting accurate SLN
detection). SLN biopsy incision(s) are then planned to allow
for adequate access and dissection for identified of nodes
identified using the gamma probe for directional surgical
guidance and activity confirmation. Suspected lymph nodes
are verified both in vivo and ex vivo.
In addition to use of the intraoperative gamma probe for
radio-guidance, portable gamma camera (PGC) technology
is available enabling another means of real-time detection,
image-guided resection, and verification of ex vivo radio-
labeled tissues including SLNs.22,23 Pre-incision intra-
operative PGC imaging can also be used to rapidly identify
discrete foci of radiotracer activity for targeted resection
along with the hand-held surgical gamma probe. After
resection, PGC imaging of the ex vivo specimen can rapidly
verify the presence or lack of radiotracer activity as well.
Likewise, PGC imaging of the surgical bed can quickly verify
complete resection (i.e., lack of focal radiotracer activity
in the surgical bed) or incomplete resection (i.e., persistent
radiotracer activity). Intraoperative PGC imaging is not
limited to 99mTc-based agents either as it has been
described in indium-111-pentetreotide for image-guided
resection of somatostatin receptor avid malignancies like
gastrinoma.24 Accordingly, the use of dual intra-operative
surgical techniques (methylene blue and intraoperative
radio-guidance) for SLN identification has been shown to
improve sensitivity for detection in utilization of both audio
and visual cues.25,26
One feature of any radio-colloid is that it possesses the
potential to transit beyond primary echelon node(s),whereby additional lymph nodes (i.e. non SLNs) may be
found to emit some degree of radioactivity and thus
become detected. Clearly the removal of all such radioac-
tive nodes, many of which may not be biologically relevant,
is impractical and defeats the purpose of SLN biopsy.
Initially historical, a common threshold of activity for a SLN
has been defined as any node demonstrating 10% or greater
radio-activity compared to the hottest node ex vivo; typi-
cally up to 4 nodes per basin. Assessment of this 10%
threshold has been validated including one study in which a
4% increase in false negative rate (FNR) was observed when
the SLN threshold was increased to 20% activity of the
hottest node and an 11% increase in FNR was observed when
only the hottest node was removed.27
Postoperative analysis
Following excision, all SLNs are submitted for histopatho-
logic analysis. Current recommendations are for excised
SLNs to undergo serial sectioning as well as hematoxylin and
eosin (H&E) staining by an experienced pathologist in order
to detect micrometastatic nodal disease. In melanoma, the
use of immuno-histochemical (IHC) staining (i.e. Melan-A,
S-100, HMB-45) is considered standard to aid identification
of nodal micrometastases and results in detection of a
higher proportion of SLNs involved with tumor.28 Similarly,
IHC techniques utilizing anti-cytokeratin antibodies (AE1/
AE3) are increasingly employed in addition to traditional
H&E methodology to detect occult nodal disease in oral
cavity/pharyngeal SCC. A higher sensitivity for occult nodal
disease detection is seen when serial step sectioning and
IHC is used compared to H&E assessment alone.29,30
Standard of care in cutaneous melanoma
Support for SLN biopsy as the standard of care in low to
intermediate grade melanoma is based on its over-
whelmingly supportive data, extensive clinical use and
incorporation into national and international consensus
statements.31 Many cases occur in younger patients as well,
highlighting the need for appropriate aggressive treatment
without undue risk in managing this malignancy. The ability
to accurately stage a disease not only guides surgical and
adjuvant treatment decisions but also identifies those for
clinical trial enrollment when needed.31
SLN biopsy is therefore an ideal strategy in melanoma as
only 20% of patients with stage I or II disease will be found
to have occult regional metastasis and therefore benefit
from lymphadenectomy. Its fidelity has been confirmed in
numerous reports showing a false negative rate under 5%
and identification that the pathologic status of the SLN is
the most important prognostic factor for recurrence and
survival.1,13 As such, SLN biopsy is the most specific and
sensitive means for regional staging in the absence of END.
As experience with SLN biopsy in cutaneous melanoma
has grown, the patient population most likely to benefit
from this technique has become more well-defined. One
prospective study used both univariate analysis and a
multivariate model to concluded patients with a Breslow
depth greater than 1 mm or with a lesion depth <1 mm and
an additional adverse feature should undergo SLN biopsy.
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regression to 1.0 mm, young age, mitotic rate 1/mm2,
angiolymphatic invasion and positive deep margin.32 The
use of SLN biopsy has been confirmed to increase disease-
free survival and melanoma-specific survival in these pa-
tient cohorts.13,33
This standardization of patient selection, pathologic
criteria and evidence-based imaging and operative tech-
niques stands as a model for future expansion of SLN use as
well as other surgical advances. The World Health Organi-
zation (WHO) has issued a statement regarding SLN biopsy
as representing the standard of care for melanoma and “a
starting point for future policies on surgery and adjuvant
treatment strategies.”34 Subsequently, SLN biopsy has
become incorporated into National Comprehensive Cancer
Network (NCCN) guidelines and recommended by American
Society of Clinical Oncology and Society of Surgical
Oncology.SLN biopsy in oral cavity squamous cell
carcinoma
Using cutaneous melanoma as a model for success, SLN bi-
opsy has been extensively explored in oral cavity squamous
cell carcinoma (OSCC). Traditional efforts to identify the
presence of occult regional nodal disease in cN0 OSCC pa-
tients utilizing history, physical exam, and radiologic imaging
lacks sufficient sensitivity and specificity in that regard.6,7 As
such, the use of END has been used routinely in the surgical
management of OSCC in cases where risk of occult metas-
tases is>20%. Unfortunately END is invasive, associated with
substantial potential for morbidity, and furthermore can be
argued to be unnecessary in a large proportion of patient-
sdi.e. 70e80% of individuals with T1 or T2 oral cavity car-
cinoma who ultimately prove without nodal
metastases.5,35e38 As such, less invasivemethods such as SLN
biopsyused topredict the status of regional lymphnodebasin
in cN0 patients may serve to reduce patient morbidity asso-
ciated with END (scar/contour deformity, facial/shoulder
weakness, neuropathic pain/numbness).16,39,40
The accuracy of SLN biopsy for OCSCC has been pub-
lished in numerous well-constructed, prospective multi-
institutional studies (Table 1). In 2010, Alkureishi et al re-
ported results in 134 subjects with T1-2 N0 oral cavity or
oropharyngeal cancer who were prospectively studied as
part of a European multi-institutional trial. Patients either
underwent SLN biopsy alone or SLN biopsy in combination
with END. SLNs were identified in 93% (125/134) of casesTable 1 Summary of prospective multi-institution studies for S
Authors Subjects Radiotracer/agent
Civantos FJ, et al14 140 99mTc-sulfur colloid
Schilling C, et al15 415 99mTc nanocolloid þ blue dy
Alkureishi LW, et al16 134 99mTc colloid þ blue dye
Agrawal A, et al46 83 99mTc-tilmanocept
SLN, sentinel lymph node; OSCC, oral cavity squamous cell carcinomawith a lower rate of SLN identification for floor-of-mouth
(FOM) tumors (88% vs 96%; P Z 0.138). Overall a FNR of
9% of was seen after long term follow-up. Additionally,
when FOM tumors were analyzed separately, sensitivity and
NPV of SLN biopsy were significantly worse compared to all
other sites (80% vs 97% and 88% vs 98% respectively;
P Z 0.034).16
Similarly in 2010, the American College of Surgeons
Oncology Group published the results of a multi-
institutional cooperative group study in the United States
involving 25 institutions over a 3-year period. This study
assessed patients with T1-2 cN0 OSCC, selecting 140 sub-
jects undergoing SLN biopsy followed by planned END. In
this group, the observed NPV of SLN biopsy was 96% and a
FNR of 9.8% was seen. Similar to prior studies, SLN biopsy
results were worse for FOM tumors. In addition to disease
subsite, tumor size (T2 vs T1 tumors) as well as lesser sur-
geon experience were cited as factors reducing accuracy of
SLN biopsy.14
More recently, a 3-year update on the Sentinel European
Node Trial (SENT) trial sponsored by the European Organi-
zation for Research and Treatment of Cancer (EORTC) has
been reported. In this trial, since 2005, 14 European cen-
ters recruited 415 patients with T1-2 N0 oral cavity SCC
having undergone SLN biopsy followed by therapeutic neck
dissection (for positive SLN) vs observation with a median
follow-up of 52 months. A SLN was identified in 99.5% of
cases with 23% (94/415) positivity for nodal involvement.
False-negative result occurred in 15/109 patients (patients
with negative SLN biopsy who subsequently developed
regional disease) yielding a FNR of 14%. The NPV for SLN
biopsy was 95%. Interestingly, in patients who underwent
subsequent therapeutic neck dissection following identifi-
cation of positive SLN, 22/94 (23.4%) patients suffered
recurrence of disease with the majority (16 of 22 cases)
recurring in the already-operated neck.15
It is clear by these 3 multicenter, prospective trials that
SLN biopsy for OSCC is a valid and promising technique, as
evidenced by high success in identifying SLNs and consis-
tently high negative predictive value (>95%). Unlike its
counterpart in cutaneous melanoma, however, use of SLN
biopsy in oral cavity squamous carcinoma has continued to
face several challenges and caveats which have likely
served to hinder its widespread adoption for use in man-
agement of OSCC. These factors have included:
 False negative rate: despite high negative predictive
value of SLN biopsy for OSCC demonstrated in several
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Contemporary use of SLN biopsy in head and neck 121trials has ranged from 9% to 14%. Although not unrea-
sonable, FNR in this range could still be considered
suboptimal and source of unreliability when considering
SLN biopsy. Factors identified which appear to
contribute to a higher FNR include tumor subsite (i.e.
floor of mouth tumors) where the phenomenon of
“shine-through effect” can obscure identification of
relevant adjacent SLNs, larger tumors (T2 or larger le-
sions where radiotracer distribution is less uniform/
consistent), and lesser surgeon experience with SLN bi-
opsy procedures.14,16
 Lack of reliable real-time SLN information: use of
frozen section analyses for SLN assessment yields sub-
optimal sensitivity in detecting occult nodal disease with
sensitivity rates reported less than 50% in some series.41
Current SLN assessment methodology involving serial
specimen sectioning and IHC techniques requires a time-
frame of several days for reliable actionable results.
Unfortunately, this time-frame remains unconductive to
situations where a single surgical procedure is prefer-
able for both surgeons and patients–for example those
patients in whom major reconstruction is required (i.e.
microvascular free tissue transfer) where re-entry in to
the neck is not desirable, patients who are medically
fragile, or in patients in whom staged/delayed pro-
cedures would delay/prolong recommended adjuvant
treatment measures.
 Multiple SLN pathways/nodal basins: one major feature
of the head and neck is the variability of lymphatic
drainage pathways from a primary tumor to the regional
basin where it is not uncommon for multiple SLNs at
multiple levels or even contralateral neck drainage to be
identified.15 Given this potential, the procedure for SLN
biopsy carried out at multiple levels and/or neck bilat-
erally can become a technically time-consuming proce-
dure for which it could be argued that the effort/
morbidity of SLN biopsy in these cases may be on par
with that carried out during END when performed by
experienced hands. It is certainly plausible that factors
such as those above may cause even experienced head
and neck sentinel node surgeons to elect to proceed with
END rather than SLN biopsy.
Despite the noted drawbacks of traditional SLN biopsy in
OSCC, there exist several promising developing refinements
of SLN biopsy procedures which may serve to address issues
of reliability, accuracy and ease of use in this patient
population. It is hoped that recent technologic advances in
development of novel radiotracer agents may lead to im-
provements in SLN biopsy accuracy by overcoming some of
these obstacles associated with traditional agents such as
radiolabeled colloid. Due to its particulate nature and un-
standardized variation in preparation (100e1000 nm diam-
eter), 99mTc radiolabeled colloid is retained for prolonged
periods within the injection site increasing the phenome-
non of “shine-through effect” which likely contributes to
lack of identification of relevant SLN particularly for FOM
tumors which are in close proximity to relevant level I neck
lymphatics and may thus contribute to FNR associated with
SLN procedures.16,42
99mTcediethylenetriamine penta-acetic acidemannosyl
edextran (99mTc-tilmanocept; Lymphoseek; NavideaBiopharmaceuticals Inc, Dublin, OH, USA) is a novel tar-
geted radiopharmaceutical agent approved by the FDA and
European Medicines Agency for use in SLN mapping and
intraoperative procedures in cases of cutaneous melanoma,
breast cancer, and OSCC.43 Tilmanocept is a soluble syn-
thetic molecule with a dextran-10 backbone and multiple
mannose side moieties, making it a CD-206 receptoretar-
geted radiopharmaceutical with several unique properties
compared to radiolabeled colloid. First, as a soluble
molecule, it has a small diameter, and exhibits more rapid
clearance from the injection site which is hypothesized to
reduce “shine-through effect.” Second, by binding to the
CD-206 mannose-binding receptors located on nodal retic-
uloendothelial cells, it possesses specificity for nodal tis-
sues allowing sustained SLN uptake without distal lymph
node accumulation.44,45 These properties of Tilmanocept
may yield a specific advantage when used for SLN pro-
cedures for oral cavity tumors.
The efficacy of 99mTc-tilmanocept was investigated in a
prospective phase 3, multicenter, single arm study of 83
patients who underwent SLN biopsy per standard protocol
followed by planned END at the same surgical setting. At
least 1 SLN was identified in 81/83 patients (98%). Thirty-
nine patients were found to have occult nodal metastasis
based upon histopathologic assessment of SLNs and END
specimens. Importantly, only 1 false-negative occurred
with this protocol yielding a FNR of 2.6%, NPV of 97.8% and
overall accuracy of 98.8%.46 In addition this series included
20 subjects with floor of mouth tumors, 12 of whom were
identified with metastatic nodal disease, and all of whom
were identified via SLN biopsy yielding FNR of 0% for this
particular subsite.46 Of note, all of these floor of mouth
tumor patients underwent radiopharmaceutical injection
the day before surgery as mandated by protocol. The FNR
rate was not significantly different as to whether patients
underwent tracer injection the day before surgery vs in-
jection on the day of surgery suggesting leeway in injection
timing relative to planned surgery (typically within 24 h).
Interestingly, the surgeons involved in this trial were all
relatively experienced in SLN procedures which may also
have led to observed excellent results. Although a head-to-
head trial between Tilmanocept and radiocolloid has not
been reported, these results overall remain quite promising
regarding use of this agent in head and neck SLN
procedures.
Another refinement with regard to SLN procedures for
oral cavity tumors relates to pre-operative imaging and
assessment. Standard perioperative imaging techniques
with 2-dimensional planar lymphoscintigraphy has limited
value and offers little insight to lymphatic drainage pat-
terns or precise anatomic location of relevant SLNs due to
poor anatomic detail as well as shine-through via primary
site injection.16 Anatomic detailed volumetric imaging
modalities such as hybrid SPECT/CT offers surgically rele-
vant topographical orientation and delineation of SLNs in
relation to adjacent anatomy offering an advantage for
surgical planning as well as for delineation of primary tu-
mors from relevant SLNs which might otherwise be
obscured via planar imaging techniques (Fig. 1). Several
recent studies appear to suggest this advantage using
SPECT/CT over planar imaging which may further reduce
false negative results.43,46
Fig. 1 2-D conventional planar lymphoscintigraphy and fused SPECT/CT in evaluation of a patient with floor-of-mouth carcinoma
and the relationship of sentinel lymph node location to anatomic landmarks.
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pertaining to SLNs, remains a major obstacle to its routine
use in head and neck procedures. Efforts aimed toward
rapid intra-operative tumor identification in SLNs via mo-
lecular methodology currently represents an active area of
investigation. One study using automated quantitative real-
time polymerase chain reaction (qRT-PCR) to quantify
expression of 11 tumor-associated genes identified 2 gene
markers for subsequent analyses and validation testing e
pemphigus vulgaris antigen (PVA) and tumor-associated
calcium signal transducer 1 (TACSTD1), also known as
epithelial cell adhesion molecule (EpCAM). Testing of this
methodology demonstrated ability to create an automated,
reproducible, and rapid process (35 min) with high accuracy
of w96% NPV in identifying nodal tumor involvement.47 In
practice such a process, if accurate and reliable, would
practically allow for intra-operative decision making (i.e.
need for END) and thus avoid staged operative procedures.
As such, the development of practical real-time diagnostic
abilities as it pertains to SLN assessment may represent the
next most significant advancement in the management of
OSCC and thus remove a major hurdle to the use of SLN
procedures in this setting.
Additional roles for SLN procedures can be gleaned from
data regarding regional nodal behavior in OSCC. Ganly et al
reviewed 164 patients from 1985 to 2005, with early, low-
risk T1-2 oral tongue SCC treated at Memorial Sloan-
Kettering Cancer Center and Princess Margaret Cancer
Center in patients having undergone partial glossectomy
and ipsilateral END without adjuvant radiation (margin
negative, pathologic node negative). This series demon-
strated a regional recurrence rate of approximately 20%,
and surprisingly, in 39% of these cases, regional recurrence
occurred in the contralateral neck and appeared to be
linked to factors including original tumor thickness
(>4 mm).48 In the European SENT trial, contralateral neck
metastasis was also identified in 12% of cases of lateralized
oral tumors.15 This information points toward a potential
unique role that SLN procedures may play in identifying
unexpected drainage patterns for OSCC includingcontralateral neck or nodal basins outside of typical plan-
ned END which may require specific attention during either
SLN biopsy or END procedures and merit further formal
prospective study in the future.New and emerging approaches for advanced
molecular imaging
Newer developments in molecular imaging are currently
explored as a means to improve SLN efficacy and accuracy.
It has been demonstrated that 99mTc-labeled nanocolloids
can be simultaneously labeled with a near-infrared (NIR)
dye, indocyanine green (ICG), in order to facilitate real-
time fluorescent visualization of SLNs and lymphatic
drainage pathways. ICG is a dicyanine fluorescent imaging
agent that emits in the NIR spectrum around 800 nm.49 One
particular dual-labeled agent, ICGe99mTc-nanocolloid, al-
lows for conventional pre-surgical imaging with lympho-
scintigraphy as well as SPECT/CT and hand-held surgical
gamma probing but also enables rapid fluorescent detec-
tion of SLNs during surgery. This particular agent proved
superior for the visual detection of SLNs when compared
with standard blue dyes with a particular role in head and
neck cancer due to proximity of nodal basins.50e54
Furthermore, no apparent difference in the lymphatic
drainage patterns for the dual-labeled ICGe99mTc-nano-
colloid agent is found when compared to the conventional
99mTc-labeled nanocolloid.55 At present, there are approx-
imately 7000 optical imaging systems approved for imaging
ICG-based agents. When combined with conventional lym-
phoscintigraphy and current radio-guided surgical ap-
proaches, dual-labeled imaging agents like ICGe99mTc-
nanocolloid and these intraoperative fluorescent imaging
systems promise to enhance the surgeon’s ability to rapidly
detect and completely resect fluorescently labeled
lesions.56e58
Another novel approach to improve accuracy in SLN
identification is through the use of positron-emission to-
mography (PET) agents. One such agent used is Zirconium-
Contemporary use of SLN biopsy in head and neck 12389-labeled nanocolloidal albumin which has been reported
to enable more precise localization of SLNs when compared
with conventional imaging approaches.59 Although PET-
based agents may not be easily imaged within the surgical
suite, new operative room approaches have been described
for the targeted excision of radiolabeled lymph nodes
containing the PET radiotracer fluorine-18 fluorodeox-
yglucose (18F-FDG) using existing hand-held surgical probes
and ex vivo specimen PET/CT imaging.60 Additionally real-
time optical imaging of PET-radiolabeled lymph nodes
called Cerenkov Luminescence Imaging (CLI) is now avail-
able as well. Cerenkov luminescence refers to the visible
light produced when a positron is emitted and then passes
through the aqueous medium of cells and tissues.61e63
These light photons can be readily and rapidly detected
using bioluminescence imaging systems and the in vivo CLI
for lymph nodes labeled with 18F-FDG has already been
described clinically.64 The role for the use of these newer
intraoperative adjuncts has not yet been defined but
clearly provide unique surgical advantages.
Conclusions
Sentinel lymph node biopsy procedures have become well-
established and commonplace for disease sites including
cutaneous melanoma and breast malignancy. Its use for
other sites such as oral cavity carcinoma continues to
develop with promising results from several recent pro-
spective trials. Refinements in technology including devel-
opment of novel radiopharmaceutical tracers, routine
incorporation of detailed anatomic perioperative imaging,
emerging imaging modalities, as well as increasing surgeon
experience will likely lead to improvements in use and
accuracy of this technique and improved adoption of SLN
procedures in the management of OSCC.
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